Methods, systems and kits of detecting a panel of retinopathy of prematurity-associated proteins in preterm infant
Patent Information
- Application Number
- HK62026124524
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-03-05
- Filing Date
- 2026-06-09
- Publication Date
- 2026-09-11
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202580003737.5 (22) Application Date 2025.09.11 (30) Priority Data 63 / 693,209 2024.09.11 US 63 / 767,518 2025.03.05 US (85) PCT International Application Entering National Phase Date 2026.01.15 (86) PCT International Application Application Data PCT / CN2025 / 120724 2025.09.11 (87) PCT International Application Publication Data WO2026 / 056979 EN 2026.03.19 (71) Applicant Eye Vision Research Center Limited Address 17W, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong, China Room 901-903, Building Applicant: Hong Kong Polytechnic University (72) Inventors: Lin Weiqing, Lin Quan, Shi Yinghan, Liao Kaiying, Zheng Baiwen (74) Patent Agency: Shenzhen Yibao Intellectual Property Agency (General Partnership) 44588 Patent Attorney: Wang Qin, Cao Yucun (51) Int.Cl. G01N 33 / 68 (2006.01) (54) Invention Title: Method, System and Reagent Kit for Detecting Proteome Related to Retinopathy of Prematurity (57) Abstract: A method for detecting proteome expression levels related to retinopathy of prematurity is provided. The method includes: obtaining a tear sample from a preterm infant and obtaining a protein expression profile from the tear sample; detecting a set of retinopathy-associated proteomes in the protein expression profile, including one or more upregulated and downregulated proteins; calculating the log-2 fold change (Log2FC) of each upregulated protein relative to its baseline expression level, and similarly calculating the log-2 fold change of each downregulated protein; generating a list including upregulated proteins with a log-2 fold change greater than or equal to a positive threshold and downregulated proteins with a log-2 fold change less than or equal to a negative threshold.Claims (2 pages), Description (10 pages), Drawings (8 pages), CN 122029433 A, 2026.05.12, CN 1 22 02 94 33 A. 1. A method for diagnosing retinopathy of prematurity (ROP) in a preterm infant by detecting and calculating the expression levels of a proteome associated with ROP, characterized by comprising: obtaining a tear sample from the preterm infant; extracting a protein expression profile from the tear sample; detecting the ROP-associated proteome in the protein expression profile, comprising one or more upregulated and downregulated proteins; calculating the log-2-fold change in expression level of each upregulated protein relative to its baseline expression level, and similarly calculating the log-2-fold change in expression level of each downregulated protein; and generating a protein list as molecular characteristics of ROP-associated tear biomarkers, wherein the protein list comprises: upregulated proteins whose log-2-fold change is greater than or equal to a positive threshold; and downregulated proteins whose log-2-fold change is less than or equal to a negative threshold. The upregulated proteins include one or more of the following: β2-microglobulin, fatty acid-binding protein 5, protein S100-A4, secretory globulin family 1D member 1, interleukin-1 receptor antagonist, glutathione reductase, GTP-binding nucleoprotein Ran, eukaryotic initiation factor 4A-I, polymeric immunoglobulin receptor, NAD(P)H dehydrogenase 1, cysteine-rich protein 1, membrane-associated phospholipase A2, and DNA. The dC→dU editing enzyme APOBEC-3A, chondroitin acidic protein 1, C-X-C motif chemokine 17; and the downregulated proteins include one or more of the following: antithrombin III, fructose-1,6-bisphosphatase 1, apolipoprotein D, apolipoprotein A-I, apolipoprotein A-IV, adenosine monophosphate kinase isoenzyme 1, β-hexosamine alpha subunit, hemoglobin-binding protein, alpha-fetoprotein, serum transferrin, AMBP protein, interproteases inhibitor heavy chain H2, transthyretin, retinol-binding protein 4, apolipoprotein H, α-2-HS-glycoprotein, ganglioside GM2 activating protein. 2. The method of claim 1, wherein the positive threshold is 0.58. 3. The method of claim 1, wherein the negative threshold is -0.58. 4. The method of claim 1, wherein the baseline expression level is obtained by detecting relative proteins in tear samples from healthy preterm infants. 5. The method according to claim 1, wherein the protein expression spectrum is acquired by a data independent acquisition mass spectrometer and quantified by a machine learning-based analysis step.6. A system for diagnosing retinopathy of prematurity (ROP) in preterm infants by detecting and calculating the expression levels of a proteome associated with ROP, characterized in that it comprises: a sample collection module configured to collect tear samples from preterm infants; a protein analysis module configured to extract a protein expression profile from the tear samples; a protein detection module configured to detect the expression levels of a proteome associated with ROP in the protein expression profile, wherein the proteome includes one or more upregulated proteins and one or more downregulated proteins; and a calculation module configured to: calculate the log-2 fold change of each upregulated protein relative to a baseline expression level; calculate the log-2 fold change of each downregulated protein relative to a baseline expression level; and generate a protein list as molecular characteristics of tear biomarkers associated with ROP to facilitate subsequent clinical decision-making or risk stratification, wherein the protein list includes: upregulated proteins whose log-2 fold change is greater than or equal to a positive threshold; and claims 1 / 2 page 2 CN 122029433 A The downregulated protein is defined as a logarithmic fold change value less than or equal to a negative threshold. 7. The system according to claim 6, wherein the upregulated protein comprises one or more of the following: β2 microglobulin, fatty acid-binding protein 5, protein S100-A4, secretory globulin family 1D member 1, interleukin-1 receptor antagonist, glutathione reductase, GTP-binding nucleoprotein Ran, eukaryotic initiation factor 4A-I, polymeric immunoglobulin receptor, NAD(P)H dehydrogenase 1, cysteine-rich protein 1, membrane-associated phospholipase A2, DNA dC→dU editing enzyme APOBEC-3A, chondroitin 1, and C-X-C motif chemokine 17. 8. The system of claim 6, wherein the downregulated protein comprises one or more of the following: antithrombin III, fructose-1,6-bisphosphatase 1, apolipoprotein D, apolipoprotein A-I, apolipoprotein A-IV, adenosine monophosphate kinase isoenzyme 1, β-hexosamine alpha subunit, hemoglobin-binding protein, alpha-fetoprotein, serum transferrin, AMBP protein, interproteases inhibitor heavy chain H2, transthyretin, retinol-binding protein 4, apolipoprotein H, α-2-HS-glycoprotein, and ganglioside GM2 activating protein. 9. The system of claim 6, wherein the baseline expression level is obtained by detecting relative proteins in tear samples from healthy preterm infants. 10. The system of claim 6, wherein the positive threshold is 0.58 and the negative threshold is -0.58. 11. The system of claim 6, wherein the protein analysis module comprises a data-independent acquisition mass spectrometer.12. A kit for detecting retinopathy of prematurity-related proteome in preterm infants, characterized in that it comprises: a protein detection method for detecting the presence or expression level of retinopathy of prematurity-related proteome in preterm infant biological samples; wherein the retinopathy of prematurity-related proteome includes: β2-microglobulin, fatty acid-binding protein 5, protein S100-A4, secretory globulin family 1D member 1, interleukin-1 receptor antagonist, glutathione reductase, GTP-binding nucleoprotein Ran, eukaryotic initiation factor 4A-I, polymeric immunoglobulin receptor, NAD(P)H dehydrogenase 1, cysteine-rich protein 1, membrane-associated phospholipase A2, and DNA. The following proteins are included in the kit: dC→dU editing enzyme APOBEC-3A, chondroitin 1, C-X-C motif chemokine 17, antithrombin III, fructose-1,6-bisphosphatase 1, apolipoprotein D, apolipoprotein A-I, apolipoprotein A-IV, adenosine monophosphate kinase isoenzyme 1, β-hexosinosinase α subunit, hemoglobin-binding protein, alpha-fetoprotein, serum transferrin, AMBP protein, interproteases inhibitor heavy chain H2, transthyretin, retinol-binding protein 4, apolipoprotein H, α-2-HS-glycoprotein, and ganglioside GM2 activating protein. 13. The kit according to claim 12, wherein the protein detection method comprises mass spectrometry, antibody immunoassay, protein chip, or aptamer detection system. 14. The kit according to claim 12, wherein the biological sample comprises tears, blood, serum, or plasma samples. Claims 2 / 2 Page 3 CN 122029433 A Method, System, and Kit for Detecting the Proteome of Retinopathy of Prematurity in Premature Infants Cross-Reference to Related Applications
[0001] This application claims priority to U.S. Provisional Patent Application No. 63 / 693,209, filed September 11, 2024, and U.S. Provisional Patent Application No. 63 / 767,518, filed March 5, 2025, the disclosures of which are incorporated herein by reference in their entirety. Technical Field
[0002] This invention relates to the fields of medicine and bioinformatics. More specifically, this invention relates to methods, systems, and kits for detecting the proteome of retinopathy of prematurity in premature infants. Background Art
[0003] Retinopathy of prematurity is a serious ophthalmic disease characterized by abnormal proliferation of retinal vessels in premature infants. This pathological neovascularization typically occurs at the junction of the vascular and avascular areas of the immature retina and may further form fibrous scar tissue. Contraction of this fibrotic tissue can eventually lead to retinal detachment, resulting in permanent vision loss. Therefore, retinopathy of prematurity (ROP) is recognized as a leading cause of preventable childhood blindness worldwide. With advancements in neonatal care and increasing survival rates for premature infants, the global incidence of ROP has also risen significantly.Although retinopathy of prematurity (ROP) is clinically relevant, its underlying etiology and pathophysiological mechanisms are not fully understood.
[0004] ROP progresses rapidly and severely, and can be clinically divided into five stages: the first stage is the appearance of a slight boundary between the vascular and avascular retina; the second stage is the formation of ridges; the third stage is the appearance of pathological angiogenesis; the fourth stage is partial retinal detachment; and the fifth stage is complete retinal detachment. Furthermore, ROP can be classified into three concentric retinal zones centered on the optic disc based on the location and morphology of the lesions: Zone I is the innermost circle, containing the macula and the optic disc; Zone II is the mid-peripheral retina; and Zone III is the crescent-shaped peripheral retina. Timely identification of disease progression is crucial, as early intervention with anti-vascular endothelial growth factor (VEGF) therapy or laser photocoagulation can effectively prevent disease progression and maintain vision. Timely detection of disease progression is extremely important, as early intervention with anti-VEGF therapy or laser photocoagulation can control the disease and protect vision.
[0005] Currently, indirect fundus examination is the gold standard for screening retinopathy of prematurity (ROP) in clinical practice. However, this method requires specialized instruments and is highly dependent on the subjective interpretation of experienced ophthalmologists. Therefore, different clinicians will inevitably have different interpretations of subtle retinal changes, and their diagnoses of disease staging may also differ, often leading to inconsistencies in diagnosis. In addition, the examination process usually requires repeated pupil dilation using cycloplegic agents or mydriatics, which may cause physiological burden and side effects for vulnerable premature infants. Although there are imaging-based ROP screening methods, their prognostic capabilities are limited. They can usually only detect the disease after it occurs and cannot provide effective prediction or early risk assessment. Therefore, many premature infants do not receive timely treatment, resulting in irreversible retinal damage.
[0006] Therefore, there is still a great need in clinical practice for a reliable and non-invasive diagnostic detection technology that can detect or predict ROP through measurable biomarkers. Traditional diagnostic methods, such as direct sampling of retinal tissue, are highly invasive and risky, and may lead to permanent retinal damage. Current technologies cannot accurately predict the likelihood of retinopathy of prematurity (ROP) in high-risk preterm infants. Therefore, this invention provides a biomarker-based, non-invasive approach (page 1 / 10, CN 122029433 A) to address this clinical need. This approach allows for early detection or prediction of ROP, facilitating timely clinical treatment and reducing the risk of blindness.
[0007] The purpose of this invention is to provide a method and system for solving the aforementioned technical problems.
[0008] According to a first aspect of the present invention, a method for detecting the expression levels of a proteome related to retinopathy of prematurity (ROP) in a preterm infant is provided. The method includes: obtaining a tear sample from the preterm infant; extracting a protein expression profile from the tear sample; and detecting a ROP-related proteome in the protein expression profile, which includes one or more upregulated and downregulated proteins.
[0009] The method further includes: calculating a log2 fold change (Log2FC) of each upregulated protein relative to its baseline expression level, and similarly calculating a log2 fold change of each downregulated protein; and generating a list including upregulated proteins with a log2 fold change greater than or equal to a positive threshold and downregulated proteins with a log2 fold change less than or equal to a negative threshold.
[0010] According to one embodiment of the present invention, the upregulated protein includes one or more of the following: β2 microglobulin (B2M), fatty acid-binding protein 5 (FABP5), protein S100-A4 (S100A4), secretory globulin family 1D member 1 (SCGB1D1), interleukin-1 receptor antagonist (IL1RN), glutathione reductase (GSR), GTP-binding nucleoprotein Ran (RAN), eukaryotic initiation factor 4A-I (EIF4A1), polymeric immunoglobulin receptor (PIGR), NAD(P)H dehydrogenase 1 (NQO1), cysteine-rich protein 1 (CRIP1), membrane-associated phospholipase A2 (PLA2G2A), DNA dC→dU editing enzyme APOBEC-3A (APOBEC3A), chondroitin acidic protein 1 (CRTAC1), and C-X-C motif chemokine 17 (CXCL17).
[0011] According to one embodiment of the present invention, the downregulated proteins include one or more of the following: antithrombin III (SERPINC1), fructose-1,6-bisphosphatase 1 (FBP1), apolipoprotein D (APOD), apolipoprotein A-I (APOA1), apolipoprotein A-IV (APOA4), adenosine monophosphate kinase isoenzyme 1 (AK1), β-hexosinosinase α subunit (HEXA), hemoglobin-binding protein (HPX), alpha-fetoprotein (AFP), serum transferrin (TF), AMBP protein (AMBP), interstitial trypsin inhibitor heavy chain H2 (ITIH2), transthyretin (TTR), retinol-binding protein 4 (RBP4), apolipoprotein H (APOH), α-2-HS-glycoprotein (AHSG), and ganglioside GM2 activating protein (GM2A).
[0012] According to one embodiment of the present invention, the positive threshold is 0.58.
[0013] According to one embodiment of the present invention, the negative threshold is -0.58.
[0014] According to one embodiment of the present invention, the baseline performance is obtained by detecting tear samples from healthy premature infants.
[0015] According to one embodiment of the present invention, the protein expression profile is acquired by a data independent acquisition (DIA) mass spectrometer and quantified by a machine learning-based analysis process.
[0016] According to a second aspect of the present invention, a system for detecting the expression levels of a proteome associated with retinopathy of prematurity is provided, comprising: a sample acquisition module configured to collect tear samples from preterm infants; a protein analysis module configured to extract a protein expression profile from the tear samples; and a protein detection module configured to detect the expression levels of a proteome associated with retinopathy of prematurity in the protein expression profile, wherein the proteome includes one or more upregulated proteins and one or more downregulated proteins.
[0017] The system further includes a calculation module configured to: calculate the logarithmic twofold change value of each upregulated protein relative to a baseline expression level; calculate the logarithmic twofold change value of each downregulated protein relative to a baseline expression level; and generate a list including upregulated proteins whose logarithmic twofold change value is greater than or equal to a positive threshold and downregulated proteins whose logarithmic twofold change value is less than or equal to a negative threshold. Instruction manual 2 / 10 pages 5 CN 122029433 A
[0018] According to an embodiment of the present invention, the upregulated protein includes one or more of the following: β2 microglobulin, fatty acid-binding protein 5, protein S100-A4, secretory globulin family 1D member 1, interleukin-1 receptor antagonist, glutathione reductase, GTP-binding nucleoprotein Ran, eukaryotic initiation factor 4A-I, polymeric immunoglobulin receptor, NAD(P)H dehydrogenase 1, cysteine-rich protein 1, membrane-associated phospholipase A2, DNA dC→dU editing enzyme APOBEC-3A, chondroitin acidic protein 1, C-X-C motif chemokine 17 The downregulated proteins include one or more of the following: antithrombin III, fructose-1,6-bisphosphatase 1, apolipoprotein D, apolipoprotein A-I, apolipoprotein A-IV, adenosine monophosphate kinase isoenzyme 1, β-hexosamine alpha subunit, hemoglobin-binding protein, alpha-fetoprotein, serum transferrin, AMBP protein, interproteases inhibitor heavy chain H2, transthyretin, retinol-binding protein 4, apolipoprotein H, α-2-HS-glycoprotein, and ganglioside GM2 activating protein.
[0019] According to one embodiment of the present invention, the baseline expression is obtained by detecting tear samples from healthy preterm infants.
[0020] According to one embodiment of the present invention, the positive threshold is 0.58, and the negative threshold is -0.58.
[0021] According to one embodiment of the present invention, the protein analysis module includes a data-independent acquisition mass spectrometer.
[0022] According to a third aspect of the present invention, a kit for detecting retinopathy of prematurity-related proteomes (ROP-R) in preterm infants is provided, comprising a protein detection method for detecting the presence or expression level of ROP-R in preterm infant biological samples. The ROP-R includes one or more of the following: β2-microglobulin, fatty acid-binding protein 5, protein S100-A4, secretory globulin family 1D member 1, interleukin-1 receptor antagonist, glutathione reductase, GTP-binding nucleoprotein Ran, eukaryotic initiation factor 4A-I, polymeric immunoglobulin receptor, NAD(P)H dehydrogenase 1, cysteine-rich protein 1, membrane-associated phospholipase A2, DNA dC→dU editing enzyme APOBEC-3A, chondroitin 1, C-X-C motif chemokine 17, antithrombin III, fructose-1,6-bisphosphatase 1, apolipoprotein D, apolipoprotein A-I, etc. Apolipoprotein A-IV, adenosine monophosphate kinase isoenzyme 1, β-hexosamine alpha subunit, hemoglobin-binding protein, alpha-fetoprotein, serum transferrin, AMBP protein, interstitial trypsin inhibitor heavy chain H2, transthyretin, retinol-binding protein 4, apolipoprotein H, α-2-HS-glycoprotein, ganglioside GM2 activating protein.
[0023] According to one embodiment of the present invention, the protein detection method includes mass spectrometry, antibody immunoassay, protein chip or aptamer detection system.
[0024] According to one embodiment of the present invention, the biological sample includes tear, blood, serum or plasma samples.
[0025] Referring to the accompanying drawings, embodiments of the present invention will be described in more detail below, wherein:
[0026] FIG1 is a flowchart of a method for detecting the expression levels of proteomes related to retinopathy of prematurity according to an embodiment of the present invention;
[0027] FIG2 is a schematic block diagram of a system for detecting the expression levels of proteomes related to retinopathy of prematurity according to an embodiment of the present invention;
[0028] FIG3A-3D show the characteristics of tear samples, wherein FIG3A shows the sex ratio; FIG3B shows the statistics of corrected age of preterm infants; FIG3C shows the weight; and FIG3D shows a histogram of the severity of the region and stage of retinopathy of prematurity as assessed by an ophthalmologist;
[0029] FIG4A-4B show tear protein volcano maps quantified by two analytical procedures, wherein FIG4A is using DIA-NN software in database-free mode; and FIG4B is PeakView software with a spectral database;
[0030] FIG5 shows proteins with different expression levels in the analysis results of DIA-NN and PeakView software;
[0031] Figure 6 shows proteins with different expression levels in both the database-free DIA-NN software quantitative analysis and the Spectronaut software analysis results; Specification 3 / 10 pages 6 CN 122029433 A
[0032] Figures 7A and 7B show functional enrichment visualizations, where Figure 7A is biological process enrichment; Figure 7B is molecular function enrichment; and
[0033] Figure 8 shows the receiver operating characteristic (ROC) analysis of a retrospective analysis of the protein SERPINC1, with an area under the curve of 0.758. Detailed Description
[0034] In the following description, methods and systems for detecting proteins associated with retinopathy of prematurity are listed as preferred embodiments. It will be apparent to those skilled in the art that modifications, including additions and / or substitutions, can be made without departing from the scope and spirit of the invention. Specific details may be omitted below to avoid obscuring the invention; however, this document is prepared to enable those skilled in the art to practice the techniques disclosed herein without excessive experimentation.
[0035] When immature retinal vessels have not yet extended to the retinal margin, retinopathy of prematurity may develop. Its severity is usually divided into five stages. The first stage is when a white dividing line appears at the junction of the vascularized and avascularized retina; in the second stage, a ridge with height and width is formed at the junction of the vascular retina and the peripheral retina; in the third stage, abnormal angiogenesis begins to appear at the ridge, and vascular growth and proliferation can also be observed within the ridge; in the fourth stage, partial retinal detachment occurs, at which point vitreoretinal surgery may be required; and in the fifth stage, the retina is completely detached, treatment is ineffective, and ultimately permanent vision loss occurs.Furthermore, the location of retinopathy of prematurity (ROP) lesions can be divided into three regions centered on the optic disc: Region I, a small circular region centered on the optic disc, with a radius twice the distance from the macula to the center of the optic disc; Region II, an outer ring region surrounding Region I, extending towards the nasal retinal margin; and Region III, a crescent-shaped region located in the temporal retina.
[0036] According to a first aspect of the present invention, a method for detecting the expression levels of proteomes related to ROP in preterm infants is provided. As shown in FIG1, the method first includes obtaining tear samples from the preterm infants (step S101), wherein minimally invasive techniques can be used to collect tears, for example, using Schirmer test strips or other ophthalmic sampling devices to collect a sufficient amount of tear samples from the ocular surface.
[0037] After obtaining the sample, the tear sample is processed to obtain a complete protein expression profile (step S102). In some embodiments, the processing of the tear sample includes steps such as protein separation, denaturation, enzymatic hydrolysis, and further preparation of peptide fragments suitable for mass spectrometry analysis. Subsequently, high-throughput proteomic analysis of the protein expression profile is performed to detect and quantify the expression level of the target protein (step S103). In a preferred embodiment, the protein expression profile is acquired by a data-independent acquisition mass spectrometer to provide high accuracy, high reproducibility, and high coverage tear protein quantification; and the obtained data can be further processed by machine learning-based analysis methods (e.g., neural network-driven algorithms) to improve detection accuracy and analyze its complex expression patterns.
[0038] In one embodiment, the method particularly focuses on detecting the expression levels of a predefined proteome associated with retinopathy of prematurity. This proteome includes upregulated and downregulated proteins associated with the pathophysiology of retinopathy of prematurity. The upregulated proteins include one or more of the following: β2-microglobulin, fatty acid-binding protein 5, protein S100-A4, secretory globulin family 1D member 1, interleukin-1 receptor antagonist, glutathione reductase, GTP-binding nucleoprotein Ran, eukaryotic initiation factor 4A-I, polymeric immunoglobulin receptor, NAD(P)H dehydrogenase 1, cysteine-rich protein 1, membrane-associated phospholipase A2, DNA dC→dU editing enzyme APOBEC-3A, chondroitin 1, and C-X-C motif chemokine 17.
[0039] On the other hand, the downregulated protein includes one or more of the following: antithrombin III, fructose-1,6-bisphosphatase 1, apolipoprotein D, apolipoprotein A-I, apolipoprotein A-IV, adenosine monophosphate kinase isoenzyme 1, β-hexosinosinase α subunit, hemoglobin-binding protein, alpha-fetoprotein, serum transferrin, AMBP protein, interproteases inhibitor heavy chain H2, transthyretin protein, retinol-binding protein 4, apolipoprotein H, α-2-HS-glycoprotein, and ganglioside GM2 activating protein.
[0040] To assess the degree of difference in the expression of the above proteins in preterm infant tear samples, the method further calculates the logarithmic 2-fold change value of each protein (step S104). More specifically, for upregulated proteins in the proteome, the performance level measured in the tear samples of the tested preterm infants is compared with its corresponding baseline performance level to obtain the log-2-fold change value of the upregulated protein; and for downregulated proteins, the log-2-fold change value of the downregulated protein is calculated using the same method. Preferably, the baseline performance level is obtained by calculating the performance level dataset of the corresponding protein detected in the tear samples of healthy preterm infants who have not been diagnosed with retinopathy of prematurity.
[0041] After completing the calculation of the log-2-fold change value, the method further generates a list of proteins that meet the judgment threshold conditions (step S105). More specifically, upregulated proteins with a log-2-fold change value greater than or equal to a preset positive threshold (preferably 0.58) are included in the list; and downregulated proteins with a log-2-fold change value less than or equal to a preset negative threshold (preferably -0.58) are also included in the list. This protein list can serve as a set of tear molecular markers associated with retinopathy of prematurity to facilitate subsequent clinical decision-making or risk stratification assessment.
[0042] According to an embodiment of the present invention, a robust, minimally invasive, and data-driven method can be provided to detect potential biomarkers for the risk of retinopathy of prematurity (ROP) in preterm infants. Through quantitative proteomics and machine learning-based analysis, the present invention can identify molecular changes associated with ROP at an early stage, thereby enabling timely diagnosis and clinical intervention.
[0043] According to a second aspect of the present invention, a system for detecting the expression levels of proteomes associated with ROP is provided. As shown in FIG2, the system 200 can perform multi-stage operations. First, it includes a sample acquisition module 201 that can receive tear samples obtained from preterm infants. The sample acquisition module 201 may include sampling tools, such as Schirmer test strips or microcapillary sampling devices, to obtain tear samples from the ocular surface in a minimally invasive manner.
[0044] The system 200 further includes a protein analysis module 202.After tear sample collection is completed, the sample is transferred to protein analysis module 202, from which a protein expression profile is extracted. Protein analysis module 202 can perform protein stabilization, cleavage, reduction, alkylation, enzymatic digestion (e.g., trypsin digestion), and subsequent peptide purification. In a preferred configuration, protein analysis module 202 includes a data-independent acquisition mass spectrometer for high-throughput and reproducible tear protein quantification. This data-independent acquisition process can be combined with neural network-based computational processes or other machine learning-driven algorithms to support spectral deconvolution, protein identification, and quantification.
[0045] System 200 further includes protein detection module 203. After protein analysis is completed, the sample is transferred to protein detection module 203 to detect the expression levels of a set of proteomics-related proteins in the protein expression profile. This proteome includes one or more upregulated proteins and one or more downregulated proteins.
[0046] In one embodiment, the upregulated protein comprises one or more of the following: β2 microglobulin, fatty acid-binding protein 5, protein S100-A4, secretory globulin family 1D member 1, interleukin-1 receptor antagonist, glutathione reductase, GTP-binding nucleoprotein Ran, eukaryotic initiation factor 4A-I, polymeric immunoglobulin receptor, NAD(P)H dehydrogenase 1, cysteine-rich protein 1, membrane-associated phospholipase A2, DNA dC→dU editing enzyme APOBEC-3A, chondroitin acidic protein 1, and C-X-C motif chemokine 17.
[0047] On the other hand, the downregulated protein includes one or more of the following: antithrombin III, fructose-1,6-bisphosphatase 1, apolipoprotein D, apolipoprotein A-I, apolipoprotein A-IV, adenosine monophosphate kinase isoenzyme 1, β-hexosamine alpha subunit, hemoglobin-binding protein, alpha-fetoprotein, serum transferrin, AMBP protein, interproteases inhibitor heavy chain H2, transthyretin, retinol-binding protein 4, apolipoprotein H, α-2-HS-glycoprotein, and ganglioside GM2 activating protein. Specification 5 / 10 pages 8 CN 122029433 A
[0048] Furthermore, the system 200 also includes a calculation module 204 for performing multiple calculation steps. These calculation steps include calculating the log-twofold change in the upregulated expression of each upregulated protein relative to the corresponding baseline expression; and calculating the log-twofold change in the downregulated expression of each downregulated protein relative to the corresponding baseline expression. The baseline expression levels of the upregulated and downregulated proteins were derived from tear samples collected from healthy preterm infants who did not exhibit symptoms of retinopathy of prematurity. This dataset serves as a reference dataset, providing a control benchmark to identify significant differences in protein expression levels associated with disease development.
[0049] After calculating the log-2 fold change value, the calculation module 204 of the system 200 further generates a list, which includes: (i) upregulated proteins with a log-2 fold change value greater than or equal to a preset positive threshold, and (ii) downregulated proteins with a log-2 fold change value less than or equal to a preset negative threshold. In one embodiment, the positive threshold is 0.58 and the negative threshold is -0.58, which are commonly used and statistically validated fold change cutoff values in protein somatic expression analysis.
[0050] In summary, the system 200 provides an integrated platform combining biosampling, mass spectrometry analysis, and computational analysis to detect and quantify biomarkers related to retinopathy of prematurity in the tears of preterm infants. According to its output, i.e., a list of retinopathy of prematurity-related proteins with significant expression changes, it is beneficial for diagnosis, prognosis, or treatment guidance in neonatal clinical care.
[0051] According to a third aspect of the present invention, a kit for detecting the proteome related to retinopathy of prematurity is provided. This kit includes a protein assay for detecting the presence or expression levels of proteins associated with retinopathy of prematurity (ROP) in biological samples from preterm infants. The proteome includes one or more of the following: β2-microglobulin, fatty acid-binding protein 5, protein S100-A4, secretory globulin family 1D member 1, interleukin-1 receptor antagonist, glutathione reductase, GTP-binding nucleoprotein Ran, eukaryotic initiation factor 4A-I, polymeric immunoglobulin receptor, NAD(P)H dehydrogenase 1, cysteine-rich protein 1, membrane-associated phospholipase A2, DNA dC→dU editing enzyme APOBEC-3A, chondroitin 1, and C-X-C motif chemokine 17. Antithrombin III, fructose-1,6-bisphosphatase 1, apolipoprotein D, apolipoprotein A-I, apolipoprotein A-IV, adenosine monophosphate kinase isoenzyme 1, β-hexosamine alpha subunit, hemoglobin-binding protein, alpha-fetoprotein, serum transferrin, AMBP protein, interproteases inhibitor heavy chain H2, transthyretin, retinol-binding protein 4, apolipoprotein H, α-2-HS-glycoprotein, ganglioside GM2 activating protein. The proteins listed above, whether used alone or in combination, can serve as biomarkers for detecting disease states or risks and have reliability and reproducibility in clinical applications.
[0052] The term "protein assay" as used herein broadly encompasses any detection technique capable of identifying, quantifying, or characterizing a target protein, and is therefore not limited to a single analytical method, but includes all techniques capable of reliably detecting or measuring the expression levels of one or more proteins associated with retinopathy of prematurity.
[0053] In some embodiments, the protein assay of this kit may include mass spectrometry-based assays.For example, liquid chromatography-tandem mass spectrometry (LC-MS / MS) can be used to quantitatively analyze target peptides with high sensitivity; independently acquired proteomics analysis can comprehensively analyze complex samples; multiple reaction monitoring (MRM) can accurately quantify specific target proteins; and matrix-assisted laser desorption / ionization time-of-flight mass spectrometry (MALDI-TOF) can rapidly and with high throughput identify proteins. Depending on the laboratory equipment and actual needs, a suitable mass spectrometry technique can be selected as the protein detection method.
[0054] In some embodiments, the protein detection method may include antibody-based immunoassay methods. Suitable forms of immunoassay include enzyme-linked immunosorbent assay (ELISA) for high-throughput quantitative detection in microplates; Western blotting to confirm the presence and molecular weight of proteins through separation and immunoassay; and Luminex bead multiplex immunoassay to simultaneously measure multiple retinopathy of prematurity-related proteins in a single sample. This antibody-based detection method helps improve compatibility with clinical and research laboratories.
[0055] In another embodiment, the protein detection method may include a protein chip in which immobilized antibodies or aptamers specifically bind to proteins in the proteome associated with retinopathy of prematurity (ROP). Such chips can perform high-throughput screening of multiple proteins in limited samples, particularly suitable for precious or low-volume clinical samples such as preterm infant tears.
[0056] In some embodiments, the protein detection method may include an aptamer-based detection system. Aptamers are short nucleic acid or peptide molecules with high binding specificity and can be designed to specifically bind to one or more ROP-associated proteins. Integrating an aptamer detection system into a kit provides a stable, reproducible, and alternative detection method suitable for traditional laboratories and real-time diagnostic platforms.
[0057] The biological samples that can be detected by the kit may include any clinically obtained preterm infant body fluids. Applicable samples include tears, blood, serum, and plasma. The flexibility in sample selection enhances the applicability of the kit in different clinical procedures and care settings, while also taking into account the low-invasiveness requirements for premature infants.
[0058] In general, the kit of the present invention provides a multifunctional and complete platform for detecting the expression of proteins related to retinopathy of prematurity in premature infants. It can also be combined with multiple detection modes, including mass spectrometry, antibody immunoassay, protein chips, and aptamer detection systems, to ensure adaptability to different laboratory environments and diagnostic needs. Furthermore, by analyzing diverse biological samples such as tears or blood, the kit of the present invention combines clinical applicability with minimally invasive features, making it suitable for the more vulnerable premature infant population.
[0059] Example
[0060] Definition of Premature Infants
[0061] Infants with a birth weight ≤ 1500 g or a gestational age ≤ 30 weeks were recruited from the Neonatal Intensive Care Unit of Queen Mary Hospital, Hong Kong as subjects. The experiment was started by a qualified pediatric ophthalmologist / retinal specialist when the subject infants reached 4 weeks of age or 31 weeks of corrected age (whichever is later).
[0062] In the cross-sectional study of retinopathy of prematurity, tear samples were collected from both preterm infants in the retinopathy of prematurity group and the non-retinopathy of prematurity group using Schirmer test strips before each mydriatic instillation. During the screening examination for retinopathy of prematurity, clinical diagnosis was made according to the latest version of the International Classification of Retinopathy of Prematurity (3rd Edition).
[0063] Example 1. Establishment of Retinopathy of Prematurity Proteome
[0064] In order to detect the expression differences of proteins associated with retinopathy of prematurity, tear samples were collected from the subjects. Sampling was performed using Schirmer test strips. The cut end of the test strip was bent at a 90-degree angle, and the lower eyelid of the subject was gently pulled. The bent end of the test strip was placed at the junction of the lower eyelid and the total amount of tear fluid absorbed should reach at least 20 mm of the marked area. The test strips were then immediately subjected to dry heat treatment to preserve the collected proteins and transported to the laboratory at room temperature in microcentrifuge tubes for proteomics analysis.
[0065] Tear samples were collected by qualified ophthalmologists at Queen Mary Hospital, Hong Kong. A total of 33 tear samples were collected from 34 premature infants, of whom 4 were diagnosed with retinopathy of prematurity (ROP) and 19 were not. Samples were collected from both eyes on the same day before clinical diagnosis, resulting in 13 ROP-related samples and 21 non-ROP samples. The subject group included 20 males and 14 females (as shown in Figure 3A). Statistical analysis showed no significant differences in corrected age (37.4 ± 2.9 vs. 35.8 ± 2.0 weeks, p = 0.103; Figure 3B) and weight (37.4 ± 2.9 g vs. 35.8 ± 2.0 g, p = 0.297; Figure 3C) between the retinopathy of prematurity (ROP) group and the non-ROP group. Most ROP cases were diagnosed as stage II in zone II (Figure 3D). Statistical comparisons were performed using an unpaired Student's t-test with unequal variances.
[0066] The total protein concentration of basal and reflex tears in the collected tear samples ranged from 3.5 to 9.5 mg / mL, with higher concentrations in neonatal tears, reaching 11-13 mg / mL. During protein extraction, each Schirmer test strip was cut into approximately 2 mm segments and placed in a new centrifuge tube.Elution with 5% SDS buffer and shaking at room temperature for 1 hour followed by centrifugation to separate the extract. Protein concentration was then determined using the biuret acid (BCA) protein quantification method. The extracted protein was reduced, alkylated, enzymatically digested, purified, and then redissolved in 0.1% formic acid solution. The final peptide concentration was adjusted to 0.5 μg / μL for subsequent mass spectrometry analysis. Data acquisition was performed using continuous window full theoretical mass spectrometry (SWATH-MS), and the obtained data were analyzed using DIA-NN software in database-free mode and PeakView software. Protein identification and quantification were performed by matching the results with a computer-generated trypsin digestion peptide profile from the UniProt human protein database using neural network dynamics analysis.
[0067] Using DIA-NN software, a total of 332 proteins were quantified at a 1% false detection rate (FDR). Among them, 53 proteins showed statistically significant differences in expression levels between the retinopathy of prematurity (ROP) and non-ROP groups, i.e., a logarithmic change ≥ 0.58 or ≤ -0.58, and p < 0.05 (as shown in Figure 4A). Simultaneously, PeakView software was used for analysis, and a spectral database based on human tears was established (obtained by independent data acquisition mass spectrometry from mixed samples). This method quantified a total of 417 proteins (1% false detection rate), of which 73 proteins showed significant differences (Figure 4B).
[0068] Further comparison of the DIA-NN and PeakView analysis procedures confirmed that 15 proteins showed significant differences in expression levels between the ROP and non-ROP groups on both platforms (p < 0.05, 1% false detection rate). Its performance level is expressed as a logarithmic change, shown as mean ± standard deviation (SD).
[0069] Proteins upregulated in the retinopathy of preterm infant group include: β2-microglobulin (1.59 ± 0.04), fatty acid-binding protein 5 (1.19 ± 0.37), protein S100-A4 (1.26 ± 0.10), secretory globulin family 1D member 1 (1.36 ± 0.12), interleukin-1 receptor antagonist (1.06 ± 0.28), glutathione reductase (0.82 ± 0), GTP-binding nucleoprotein Ran (0.65 ± 0.02), and eukaryotic initiation factor 4A-I (1.13 ± 0.76);
[0070] Proteins downregulated in the retinopathy of preterm infant group include: antithrombin III (-0.91 ± 0.35), fructose-1,6-bisphosphatase 1 (-0.92 ± 0.35), and fructose-1,6-bisphosphatase 1 (-0.92 ± 0.35). 0.14), apolipoprotein D (-1.00 ± 0.05), apolipoprotein A-I (-1.39 ± 0.60), apolipoprotein A-IV (-1.51 ± 0.40), adenosine monokinase isoenzyme 1 (-1.44 ± 0.27) (as shown in Figure 5).
[0071] To further identify proteins in tears associated with retinopathy of prematurity, this embodiment uses the direct data independent acquisition without database mode (direct-DIA+) of Spectronaut software for analysis, and performs protein identification through the human proteome containing 20,434 reviewed items. The analytical parameters adopted the standardized "BGS factory settings (preset)"; the proteolytic enzyme was set to trypsin / P, and a maximum of two missed cleavage sites were allowed; the fixed modification was cysteine carboxymethylation; the variable modifications included N-terminal acetylation and methionine residue oxidation; the peptide length was limited to 7 to 52 amino acids; the false detection rate at both the peptide precursor and protein levels was set to 1% to ensure high-confidence identification. Protein quantification was performed using the MaxLFQ algorithm with automatic normalization enabled.
[0072] Parallel analysis was performed using the database-free mode of DIA-NN software, and a predicted spectral database generated based on the same FASTA file was used for independent data acquisition, searching, and quantification; the digestive enzyme was also set to trypsin / P; a maximum of two missed cleavage sites were allowed; the modification conditions included cysteine carboxymethylation, N-terminal methionine cleavage, oxidation (M), and acetylation (N-terminus); the peptide length was limited to 7 to 52 amino acids; the precursor ion charge range was limited to 2 to 5; the mass precision and MS1 precision were both set to automatic determination. We employed cross-sample match between runs to promote comparability between samples, and used retention time (RT)-dependent cross-experimental normalization and a "robust LC" quantification strategy to improve data consistency.
[0073] Based on this proteomics analysis method, a total of 18 proteins were found to show significant differences between the retinopathy of prematurity (ROP) group and the non-ROP group (false discovery rate 1%, p < 0.05). Proteins showing upregulated expression in the ROP group included: polymeric immunoglobulin receptor (1.25±0.35), NAD(P)H dehydrogenase 1 (1.2±0.28), cysteine-rich protein 1 (1.1±0.14), membrane-associated phospholipase A2 (1.2±0), NA dC→dU editing enzyme APOBEC-3A (0.85±0.07), chondroitin 1 (0.8±0.14), and C-X-C motif chemokine 17 (1.05±0.21). Proteins with downregulated expression levels in the retinopathy of preterm infants group included: β-hexosinosinase α subunit (-0.7 ± 0.14), hemoglobin-binding protein (-0.8 ± 0.14), alpha-fetoprotein (-0.9 ± 0.14), serum transferrin (-0.8 ± 0), AMBP protein (-1.1 ± 0.14), interproteases inhibitor heavy chain H2 (-1 ± 0.14), transthyretin (-1.1 ± 0.42), retinol-binding protein 4 (-1.3 ± 0.14), apolipoprotein H (-1.15 ± 0.35), α-2-HS-glycoprotein (-1.5 ± 0.14), and ganglioside GM2 activator protein (-2.15 ± 0.64) (as shown in Figure 6). These proteins are associated with pathways related to angiogenesis, cell survival, angiogenesis, and metabolic dysregulation, showing their potential relevance in mediating the response to hypoxia and oxidative stress in the pathophysiology of retinopathy of prematurity.
[0074] Example 2. Protein functional enrichment and biomarker analysis applied to the screening of retinopathy of prematurity
[0075] Using the integrated gene ontology (GO) annotation tool of the STRING software platform, 33 proteins with differential expression levels were analyzed to determine whether there were overexpressed biological processes and molecular functions. The analysis results showed that biological processes and molecular functional pathways related to lipid metabolism and antioxidant activity were significantly enriched. Both of these pathways play key roles in angiogenesis and oxidative stress response, and these processes are also pathologically dysregulated in retinopathy of prematurity. Therefore, the enrichment results further provide important insights into the potential driving mechanisms of disease progression (as shown in Figures 7A and 7B).
[0076] To evaluate the clinical applicability of the proteome provided by the present invention, receiver operating characteristic (ROC) curve analysis was further used to analyze single protein biomarkers.Using antithrombin III as the analysis object, it showed consistent differences in various analyses. The area under the curve (AUC) of the receiver operating characteristic curve analysis results was 0.758, indicating that it has statistically significant discriminatory ability to distinguish between retinopathy of prematurity and retinopathy of prematurity. Retrospective fitting results based on antithrombin III protein expression data showed a sensitivity of 81% and a specificity of 62% (as shown in Figure 8). The above results demonstrate the diagnostic potential of individual protein biomarkers (such as antithrombin III) in non-invasive tear testing, and lay the foundation for the future development of multiple biomarker groups to improve diagnostic efficacy and clinical applicability, thereby improving diagnostic performance and clinical applicability.
[0077] As used herein, the terms “approximately,” “substantially,” “truly,” and “about / approximately” are used to describe and explain a minor variation, and when used in conjunction with an event or situation, the term can refer to the exact occurrence of the event or situation, or approximately the occurrence of the event or situation. As used herein, the term "approximately" with respect to a given value or range generally refers to a range of ±10%, ±5%, ±1%, or ±0.5% of a given value or interval, which may be understood herein as from one endpoint to another or between two endpoints. Unless otherwise stated, all ranges disclosed in this disclosure include endpoints. When referring to the same numerical value or characteristic, the term may refer to a value within ±10%, ±5%, ±1%, or ±0.5% of the average of the values.
[0078] The systems and methods disclosed according to embodiments of the invention, their functional units and modules, may be implemented by a computing device, a computer processor, or electronic circuitry, including but not limited to application-specific integrated circuits (ASICs), field-programmable gate arrays (FPGAs), central processing units (CPUs), graphics processing units (GPUs), and other programmable logic devices configured or programmed according to the teachings of the invention. Computer instructions or software code running on a computing device or programmable logic device may be performed by those skilled in the art according to the disclosure of the invention.
[0079] The methods or partial steps of the embodiments of the present invention can be executed on one or more computing devices, which may include server computers, personal computers, laptops, and mobile computing devices such as smartphones and tablets. Specification 9 / 10 pages 12 CN 122029433 A
[0080] The functional units and modules of the embodiments of the present invention can also be implemented in a distributed computing environment and / or cloud computing environment; and wherein all or part of the machine instructions can be routed through a communication network such as an intranet, a wide area network (WAN), a local area network (LAN), the Internet, and other forms of data transmission media to one or more processing devices to execute in a distributed manner.
[0081] The above description is provided for illustration and description of the invention and is not intended to be exhaustive or to limit the invention to the precise forms disclosed. Many modifications and variations will be apparent to those skilled in the art.
[0082] The above embodiments were chosen and described in order to best explain the principles of the invention and its practical application, thereby enabling others skilled in the art to understand the various embodiments of the invention and various modifications suitable for the intended particular use. Instruction manual 10 / 10 pages 13 CN 122029433 A Figure 1 Instruction manual Figure 1 / 8 pages 14 CN 122029433 A Figure 2 Instruction manual Figure 2 / 8 pages 15 CN 122029433 A Figure 3A Figure 3B Instruction manual Figure 3 / 8 pages 16 CN 122029433 A Figure 3C Figure 3D Instruction manual Figure 4 / 8 pages 17 CN 122029433 A Figure 4A Figure 4B Instruction manual Figure 5 / 8 pages 18 CN 122029433 A Figure 5 Figure 6 Instruction manual Figure 6 / 8 pages 19 CN 122029433 A Figure 7A Figure 7B Instruction manual Figure 7 / 8 pages 20 CN 122029433 A Figure 8 Instruction manual Figure 8 / 8 pages 21 CN 122029433 A.
Claims
1. A method for diagnosing retinopathy of prematurity (ROP) in preterm infants by detecting and calculating the expression levels of proteomes associated with ROP, characterized in that, include: Tear samples were obtained from the premature infants. Protein expression profiles were extracted from the tear fluid samples; The retinal disease-related proteome, including one or more upregulated and downregulated proteins, was detected in the protein expression profile. Calculate the log-2 change of each upregulated protein relative to its baseline expression level, and similarly calculate the log-2 change of each downregulated protein. as well as A list of proteins is generated as molecular characteristics of tear biomarkers related to retinopathy, wherein the protein list includes: The upregulated proteins whose log-2 change value is greater than or equal to a positive threshold; and The downregulated proteins whose log-two change value is less than or equal to the negative threshold; The upregulated proteins include one or more of the following: β2-microglobulin, fatty acid-binding protein 5, protein S100-A4, secretory globulin family 1D member 1, interleukin-1 receptor antagonist, glutathione reductase, GTP-binding nucleoprotein Ran, eukaryotic initiation factor 4A-I, polymeric immunoglobulin receptor, NAD(P)H dehydrogenase 1, cysteine-rich protein 1, membrane-associated phospholipase A2, and DNA. The dC→dU editing enzyme APOBEC-3A, chondroitin 1, CXC motif chemokine 17; and the downregulated proteins include one or more of the following: antithrombin III, fructose-1,6-bisphosphatase 1, apolipoprotein D, apolipoprotein AI, apolipoprotein A-IV, adenosine monophosphate kinase 1, β-hexosinosinase α subunit, hemoglobin-binding protein, alpha-fetoprotein, serum transferrin, AMBP protein, interproteases inhibitor heavy chain H2, transthyretin, retinol-binding protein 4, apolipoprotein H, α-2-HS-glycoprotein, and ganglioside GM2 activating protein.
2. The method according to claim 1, wherein the positive threshold is 0.
58.
3. The method according to claim 1, wherein the negative threshold is -0.
58.
4. The method of claim 1, wherein the baseline expression level is obtained by detecting relative proteins in tear samples from healthy preterm infants.
5. The method according to claim 1, wherein the protein expression spectrum is acquired by a data-independent acquisition mass spectrometer and quantified by a machine learning-based analysis step.
6. A system for diagnosing retinopathy of prematurity (ROP) in preterm infants by detecting and calculating the expression levels of proteomes associated with ROP, characterized in that, include: The sample collection module is configured to collect tear samples from premature infants. A protein analysis module is configured to extract a protein expression profile from the tear sample. A protein detection module is configured to detect the expression level of a set of proteomes associated with retinopathy of prematurity in the protein expression profile, wherein the proteomes include one or more upregulated proteins and one or more downregulated proteins. as well as The calculation module is configured as follows: Calculate the log-two change in the expression level of each upregulated protein relative to the baseline expression level; Calculate the log-two change in the expression level of each downregulated protein relative to the baseline; as well as A protein list will be generated as a molecular feature of tear biomarkers associated with retinopathy to facilitate subsequent clinical decision-making or risk stratification. This protein list will include: The upregulated proteins whose log-two change value is greater than or equal to the positive threshold; as well as The downregulated proteins are those whose logarithmic double change value is less than or equal to the negative threshold.
7. The system of claim 6, wherein the upregulated protein comprises: One or more of the following: β2 microglobulin, fatty acid-binding protein 5, protein S100-A4, secretory globulin family 1D member 1, interleukin-1 receptor antagonist, glutathione reductase, GTP-binding nucleoprotein Ran, eukaryotic initiation factor 4A-I, polymeric immunoglobulin receptor, NAD(P)H dehydrogenase 1, cysteine-rich protein 1, membrane-associated phospholipase A2, DNA dC→dU editing enzyme APOBEC-3A, chondroitin 1, and CXC motif chemokine 17.
8. The system of claim 6, wherein the downregulated protein comprises: One or more of the following: antithrombin III, fructose-1,6-bisphosphatase 1, apolipoprotein D, apolipoprotein AI, apolipoprotein A-IV, adenosine monophosphate kinase isoenzyme 1, β-hexosinosinase α subunit, hemoglobin-binding protein, alpha-fetoprotein, serum transferrin, AMBP protein, interproteases inhibitor heavy chain H2, transthyretin, retinol-binding protein 4, apolipoprotein H, α-2-HS-glycoprotein, and ganglioside GM2 activating protein.
9. The system of claim 6, wherein the baseline performance level is obtained by detecting relative protein levels in tear samples from healthy preterm infants.
10. The system of claim 6, wherein the positive threshold is 0.58 and the negative threshold is -0.
58.
11. The system of claim 6, wherein the protein analysis module includes a data-independent acquisition mass spectrometer.
12. A kit for detecting proteomes associated with retinopathy of prematurity in preterm infants, characterized in that, include: A protein assay used to detect the presence or expression level of the proteome associated with retinopathy of prematurity in biological samples of preterm infants. The proteome associated with retinopathy of prematurity (ROP) in these preterm infants includes: β2-microglobulin, fatty acid-binding protein 5, protein S100-A4, secretory globulin family 1D member 1, interleukin-1 receptor antagonist, glutathione reductase, GTP-binding nucleoprotein Ran, eukaryotic initiation factor 4A-I, polymeric immunoglobulin receptor, NAD(P)H dehydrogenase 1, cysteine-rich protein 1, membrane-associated phospholipase A2, and DNA. dC→dU editing enzyme APOBEC-3A, chondroitin 1, CXC motif chemokine 17, antithrombin III, fructose-1,6-bisphosphatase 1, apolipoprotein D, apolipoprotein AI, apolipoprotein A-IV, adenosine monophosphate kinase isoenzyme 1, β-hexosamine succinate α subunit, hemoglobin-binding protein, alpha-fetoprotein, serum transferrin, AMBP protein, interproteases inhibitor heavy chain H2, transthyretin, retinol-binding protein 4, apolipoprotein H, α-2-HS-glycoprotein, ganglioside GM2 activating protein.
13. The kit according to claim 12, wherein the protein detection method includes mass spectrometry, antibody immunoassay, protein chip or aptamer detection system.
14. The kit of claim 12, wherein the biological sample comprises tears, blood, serum or plasma.
